Poolbeg Pharma - On Track to Commence LPS Human Challenge Clinical Trial
POLB Fri, 01 Apr 2022, 07:05 BST
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, discusses the latest announcement that the Company has signed a Clinical Trial Agreement with the Centre for Human Drug Research in the Netherlands for the completion of a bacterial lipopolysaccharide ('LPS') human challenge study of POLB 001, which is due to commence in June 2022. First results are expected before the end of 2022 at which point the Company aims to rapidly monetise by partnering or out-licensing the asset to pharma/biotech for further development.
Jeremy Skillington
Chief Executive Officer
Management Team, Poolbeg Pharma
Wed, 3 Jan 2024, 11:00am GMT
Jeremy Skillington, Chief Executive Officer
Wed, 30 Nov 2022, 10:00am GMT
Jeremy Skillington, Chief Executive Officer
Mon, 5 Sep 2022, 11:00pm BST
Cathal Friel, Chairman
Wed, 27 Apr 2022, 12:00pm BST
Jeremy Skillington, Chief Executive Officer
Thu, 14 Apr 2022, 5:00pm BST
Jeremy Skillington, Chief Executive Officer
Fri, 1 Apr 2022, 7:05am BST
Jeremy Skillington, Chief Executive Officer
Fri, 25 Mar 2022, 7:05am GMT
Management Team, Poolbeg Pharma
Thu, 3 Mar 2022, 9:00am GMT
Liam Tremble, PhD, Project Manager
Thu, 24 Feb 2022, 7:05am GMT
Jeremy Skillington, Chief Executive Officer
Mon, 31 Jan 2022, 7:05am GMT
Cathal Friel, Chairman
Mon, 6 Dec 2021, 7:05am GMT
Elaine Sullivan, Poolbeg Scientific Advisory Board
Wed, 1 Dec 2021, 7:00am GMT
Cathal Friel, Chairman
Thu, 18 Nov 2021, 5:11pm GMT
Jeremy Skillington, Chief Executive Officer
Tue, 20 Jul 2021, 9:00am BST
